Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$6.19
$0.14(2.68%)
At close: 4:00 PM EDT
$6.19
$0.14(2.68%)
Day’s Range― - ―
52-Week Range$1.93 - $6.60
Previous Close$5.46
Volume4.86M
Average Volume (3M)3.67M
Market Cap
$512.25M
Enterprise Value$665.37M
Total Cash (Recent Filing)$91.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding147,198,900
10 Day Avg. Volume4,784,599
30 Day Avg. Volume3,665,986
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue80.96
Enterprise Value/Gross Profit84.67
Enterprise Value/Ebitda-8.83
Forecast
1Y Price Target
$12.00Price Target Upside93.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$6.18M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and positive equity provide Aclaris with greater financial flexibility than a highly levered development-stage biotech. This structure reduces mandatory financing pressure and leaves more capacity to direct resources toward research, clinical development, and potential partnering opportunities.
Strong Gross MarginThe company generates strong gross profitability on its existing revenue base, indicating that collaboration or licensing-related revenue can carry substantial direct economics. If revenue-producing opportunities recover, this margin profile could support attractive incremental contribution before research and operating costs.
Financing FlexibilityRefreshing the ATM facility preserves an on-demand source of capital while allowing management to choose whether and when to issue shares. That flexibility can help fund clinical development or operations through uncertain timelines, rather than requiring a single fixed financing event.
Bears Say
Contracting RevenueA sharply shrinking revenue base weakens internal funding capacity and makes the business more dependent on financing, collaborations, or future pipeline success. Continued contraction also reduces operating leverage, making it harder for existing revenue to absorb research and corporate expenses.
Persistent Cash BurnSustained cash outflows materially reduce liquidity over time and require Aclaris to secure external capital or additional collaboration proceeds. Because free cash flow remains deeply negative despite improvement from the prior year, funding needs are likely to remain central to execution.
Losses And Potential DilutionOngoing large losses and negative returns on equity indicate that shareholder capital is being consumed rather than compounded. The available ATM may help finance operations, but issuing shares to cover continuing losses can dilute existing holders and increase dependence on capital markets.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.93 and its highest was $6.60 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $512.25M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.01.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 147,198,900 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -4.245%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (93.86% Upside)
$12.00 (93.86% Upside)
Blogger Sentiment
Neutral
ACRS Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 6.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
83.15%
12-Months-Change
Fundamentals
Return on Equity
-61.65%
Trailing 12-Months
Asset Growth
-5.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$12.00
▲(93.86% Upside)
Technical Analysis
Ownership Overview
11.77% Insiders
6.96% Mutual Funds
1.04% Other Institutional Investors
68.10% Public Companies and
Individual Investors